Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hepatitis C virus (HCV) infection is common among patients with end-stage kidney disease (ESKD) and is associated with increased mortality and reduced access to kidney transplantation. Although direct-acting antivirals (DAAs) are effective in viral eradication, their long-term benefits in dialysis patients remain uncertain. We evaluated the association between DAA therapy and long-term outcomes in HCV-infected patients with ESKD.
We conducted a retrospective cohort study using the TriNetX global research network. Adults (≥18 years) with ESKD and confirmed HCV infection between 2015–2025 were included. Patients were classified as DAA-treated or untreated. The primary outcome was all-cause mortality; secondary outcomes were kidney transplantation, new cirrhosis, and incident liver cancer. Follow-up began the day after DAA start or first positive HCV RNA and continued up to 5 years. Propensity score matching (1:1) was performed to balance baseline covariates. Time-to-event analyses used Kaplan–Meier and Cox models. Sensitivity analysis restricted to individuals who survived and remained on dialysis ≥1 year. Prespecified subgroups were sex, age (<65/≥65), and baseline liver disease (cirrhosis or liver tumor). Changes in albumin and hemoglobin at 12 months were compared descriptively.
Among 7,660 patients (1,482 DAA-treated, 6,178 untreated), 1,458 matched pairs were analyzed. Over follow-up, deaths occurred in 429 (29.4%) DAA-treated vs 505 (34.6%) untreated patients (absolute risk difference −5.2%; p<0.01). DAA therapy was associated with lower mortality (hazard ratio [HR] 0.68; 95% CI 0.59–0.77; p<0.001); results persisted after excluding first-year events (HR 0.78; 95% CI 0.66–0.93; p<0.01). Kidney transplantation occurred in 183 treated vs 111 untreated patients; DAAs were associated with higher transplant likelihood (HR 1.42; 95% CI 1.02–1.62; p<0.05). New cirrhosis or liver cancer were not significantly different between groups (HR 1.07; 95% CI 0.82–1.40). Treated patients showed greater 12-month improvements in albumin and hemoglobin. Benefits were consistent across sex and age strata (e.g., males HR 0.68; females HR 0.59 for mortality) and were most pronounced for transplant among those without cirrhosis/HCC (HR 1.88; 95% CI 1.37–2.57; p<0.001).
In this large, real-world cohort, DAA therapy was associated with substantially lower 5-year mortality and greater access to kidney transplantation, without clear differences in incident cirrhosis or liver cancer. Findings support routine, timely HCV treatment in patients with ESKD to improve survival, nutritional/hematologic status, and transplant opportunities.
